Opella and Verb Biotics Partner on Gut Health Solutions
Opella and Verb Biotics have formed a strategic partnership to develop a next-generation probiotic strain. The collaboration combines Opella's global development capabilities with Verb Biotics' microbiome research.
FRANCE, March 12, 2026 – Opella announced a strategic and exclusive partnership with Verb Biotics focused on developing and commercializing a next-generation probiotic strain. This collaboration aims to enhance Opella's brand offerings with digestive wellness solutions and interconnected health benefits, leveraging Verb Biotics’ advanced microbiome technology.
Opella identifies the microbiome as a key innovation priority and views this partnership as a strategic alignment with its research and development goals. Verb Biotics, a B2B biotechnology company, specializes in discovering and supplying clinically validated microbiome ingredients for the food, beverage, and supplement industries.
The companies aim to translate rigorous science into accessible and effective health solutions. Both parties emphasize their commitment to combining pioneering research with a focus on consumer health to create transformative products.
Opella is a global player in the self-care market, specializing in Over-The-Counter (OTC) and Vitamin, Mineral, and Supplement (VMS) products. The company's mission is to simplify self-care for its half a billion consumers worldwide.